**PURPOSE:** Secondary lymphedema is a debilitating disease characterized by chronic soft tissue swelling. While there is still no cure for lymphedema, we have shown that 9-cis-Retinoic acid (9-cisRA) promotes lymphangiogenesis and reduces postsurgical lymphedema *in vivo*. Despite the resulting efficacy, little is known about the signaling pathway of 9-cisRA in this context. 9-cisRA is thought to induce its target gene responses by binding to and activating nuclear retinoid X receptors (RXRs). The aim of this study was to determine whether RXR signaling is necessary for 9-cis-RA efficacy using lymphatic endothelial cell specific conditional deletion mutant mice.

**METHODS:** Tail model of lymphedema was performed on transgenic *Prox1*-CreER^T2^ RXRα^fl/fl^mice and an age-matched control group. Superficial lymphatic vessels were severed by a 5-mm circumferential excision 2-cm distal from the tail base. The animals were treated with 9-cisRA once daily for 40 days. The distal part of the tail was imaged weekly postoperatively and tail volumes were calculated using the truncated cone formula. Tail samples 1-cm distal to the wound edge were collected and histologically analyzed to assess soft tissue thickness.

**RESULTS:** Disruption of the superficial lymphatics resulted in initial surgical edema in both the control and *RXR*α^fl/fl^groups. The *RXR*α^fl/fl^group showed a significantly less decrease in swelling at post-op days 29, 36, and 40 (\*\*p≤0.01). *RXR*α^fl/fl^mice showed significantly thicker soft tissue on post-op day 45 compared to the control (\*\*\*\*p≤0.0001).

**CONCLUSION:** Functional RXRαin lymphatic endothelial cells is necessary for 9-cisRA to reduce postsurgical lymphedema. These detailed mechanistic studies support further translation of 9-cisRA for safe clinical use in the prevention of lymphedema in humans.
